| 摘要 |
Novel pharmaceutical use for the compound (Nva)<2>-Cyclosporine, in particular use in the treatment of autoimmune diseases selected from the group consisting of: c) Juvenile diabetes type I, d) Myasthenia gravis, a) Multiple sclerosis, b) Systemic lupus erythematosus, e) Haemolytic anaemia, and f) Glomerulonephritis. |
